glp 1 agonist half life Another milestone in the evolution of GLP-1-based diabetes therapies A) Half-life extension mechanisms of

[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity

Due to their diverse structures, the pharmacokinetic profiles vary, and a prolonged half-life may be associated with an increased risk of adverse events

This was related to GLP-1 effect on AMPK activation with downstream induction of mitochondrial respiratory capacity in non-infarcted areas of the heart

Despite this, both deliberate and inadvertent use of these drugs is increasing, which has led to fetal exposure to these drugs in early pregnancy

Pharmaceutical companies have been trying to produce small-molecule GLP-1 agonists that are shelf-stable and can be taken orallyfor instance, Pfizer and Eli Lilly have developed Danuglipron and Orforglipron, respectivelybut we know very little about how they work, said Ali Gler, a neuroscientist at the University of Virginia

6 Supply chain limitations, high production costs, and the need for specialized facilities restrict the scalability of these drugs